Lymphoma & Plasma Cell Disorders
From the Journals
R-CHOP looks viable as first line in follicular lymphoma
Long-term follow-up of a randomized trial showed durable efficacy of R-CHOP with no increase in histological transformation or secondary cancers...
From the Journals
Bortezomib may unlock resistance in WM with mutations
The study tested how a bortezomib treatment combination would perform in patients with CXCR4 mutations.
Conference Coverage
Relapsed MCL: Options for treatment
There are a number of treatment options for relapsed MCL, but BTK inhibitors are particularly useful.
Conference Coverage
CLL: The initial work-up
CHICAGO – Molecular testing has prognostic value, but still doesn’t drive treatment under updated iwCLL guidelines.
Case Reports
A ‘double-hit’ bone marrow rare co-occurrence of 2 different pathologies
News
Financial burden of blood cancers in the U.S.
An analysis of more than 2,000 U.S.
News
P-BCMA-101 gains FDA regenerative medicine designation
The autologous CAR T-cell therapy being developed for multiple myeloma received regenerative medicine advanced therapy designation from the FDA....
From the Journals
Aberrant RNA editing linked to aggressive myeloma
Hyper-editing of the multiple myeloma transcriptome leads to crippling of a key DNA-repair mechanism.
News
FDA puts selinexor on fast track for DLBCL
Selinexor has received fast track designation to treat patients with previously treated DLBCL who are not eligible for certain therapies.
Feature
Report details financial burden of blood cancers
Out-of-pocket spending for acute leukemia topped $5,100 in the year after diagnosis.
News
FDA clears portable hematology analyzer
The U.S.